Market closed

Lucid Diagnostics/$LUCD

13:30

15:10

16:45

18:25

20:00

1D1W1MYTD1Y5YMAX

About Lucid Diagnostics

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Ticker

$LUCD

Sector

Health Care

Trading on

NASDAQ

Industry

Health Care Equipment & Supplies

Headquarters

New York, United States

Employees

ISIN

US54948X1090

Website

www.luciddx.com

LUCD Metrics

BasicAdvanced

$130M

-

-$1.26

-

Price and volume

Market cap

$130M

52-week high

$1.80

52-week low

$0.68

Average daily volume

1.3M

Financial strength

Current ratio

0.753

Quick ratio

0.692

Long term debt to equity

-29.812

Total debt to equity

-655.942

Interest coverage (TTM)

-2,075.96%

Management effectiveness

Return on assets (TTM)

-92.04%

Return on equity (TTM)

-1,897.35%

Valuation

Price to revenue (TTM)

17.048

Price to book

-1.78

Price to tangible book (TTM)

-1.76

Price to free cash flow (TTM)

-1.592

Growth

Revenue change (TTM)

39.89%

Earnings per share change (TTM)

-1.46%

3-year revenue growth (CAGR)

82.28%

3-year earnings per share growth (CAGR)

-6.52%

What the Analysts think about LUCD

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Lucid Diagnostics stock.

LUCD Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

LUCD Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

LUCD News

AllArticlesVideos

Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript

Seeking Alpha·5 days ago

Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst

Benzinga·1 month ago

Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LUCD

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Lucid Diagnostics stock?

Lucid Diagnostics (LUCD) has a market cap of $130M as of May 19, 2025.

What is the P/E ratio for Lucid Diagnostics stock?

The price to earnings (P/E) ratio for Lucid Diagnostics (LUCD) stock is 0 as of May 19, 2025.

Does Lucid Diagnostics stock pay dividends?

No, Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders as of May 19, 2025.

When is the next Lucid Diagnostics dividend payment date?

Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders.

What is the beta indicator for Lucid Diagnostics?

Lucid Diagnostics (LUCD) does not currently have a Beta indicator.